Nomogram to determine individualized estimates of screen-detected prostate cancer overdiagnosis
1/08/2014
Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen (PSA) level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated, according to a new study published January 6 in the Journal of the National Cancer Institute.
New discovery of biomarker to improve diagnosis, prognosis and treatment of ESCC
1/08/2014
Esophageal Squamous Cell Carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore (NUS) have discovered a biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), which has the potential to improve the diagnosis, prognosis and treatment of this disease.
Researchers target cancer stem cells in malignant brain tumors
1/08/2014
Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.
Erythropoietin and the regulation of cancer stem cell growth and survival
1/08/2014
In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.
Development of a novel dual JAK/Src kinase inhibitor
1/08/2014
Inhibitors of both JAK and Src kinases represent promising targets for cancer therapeutics because of the central importance of these kinases in tumor cell proliferation and survival. Furthermore, in cancer cells activation of JAK has been reported as a compensatory effect in response to Src inhibitor exposure.
Out-of-pocket costs play major role in treatment adherence for cancer patients
1/08/2014
The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina.
New biopsy test could pick out aggressive form of skin cancer
1/08/2014
Testing the genetic profile of immune cells next to a melanoma could lead to more accurate diagnosis to spot whether a skin cancer is aggressive enough to spread, researchers from Italy have found.Development of the research finding could enable doctors to focus cancer treatment on skin cancer patients who need it - while sparing the harm of intervening when patients do not need it.
Researchers link protein with breast cancer's spread to the brain
1/08/2014
A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain.Brain metastasis is a terrifying complication of advanced breast cancer, with a grim prognosis and few treatment options.
Cell Therapeutics, Inc. (CTI) has reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for PIXUVRI(®) (pixantrone).
Online colorectal cancer risk calculator created
1/07/2014
Researchers at Cleveland Clinic have developed a new tool called CRC-PRO that allows physicians to quickly and accurately predict an individual's risk of colorectal cancer, as published in the current edition of the Journal of the American Board of Family Medicine.